Navigation Links
ViroPharma to Release 2011 Third Quarter Financial Results on October 27, 2011
Date:10/19/2011

EXTON, Pa., Oct. 19, 2011 /PRNewswire/ -- ViroPharma Incorporated's (Nasdaq: VPHM) third quarter financial results for 2011 are expected to be released on Thursday, October 27, 2011 before the open of the U.S. financial markets.

The company will host a conference call and live audio webcast at 8:00 a.m. Eastern Time on the same day.  During the conference call, ViroPharma management will discuss the 2011 third quarter financial results and other business.

The press release and the live webcast of the conference call will be accessible via ViroPharma's corporate website at http://www.viropharma.com.  An audio archive will be available at the same address until November 18, 2011.  To participate in the conference call, please dial (888) 299-4099 (domestic) and (302) 709-8337 (international).  After placing the call, please tell the operator you wish to join the ViroPharma investor conference call.  

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing novel solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options.  Our goal is to provide rewarding careers to employees, to create new standards of care in the way serious diseases are treated, and to build international partnerships with the patients, advocates, and health care professionals we serve. 

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's website, http://www.viropharma.com/. The company encourages investors to consult these sections for more information on ViroPharma and our business.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreichs Ataxia
2. ViroPharma Announces Additional Securities Repurchase Program
3. ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20)
4. ViroPharmas Buccolam® (Midazolam, Oromucosal Solution) Granted European Marketing Authorization for Treatment of Acute Seizures
5. ViroPharma to Participate in the Stifel Nicolaus 2011 Healthcare Conference
6. ViroPharma Announces Positive CHMP Opinion for Buccolam® (Midazolam, Oromucosal Solution) in the European Union
7. ViroPharmas Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE)
8. ViroPharma to Participate in the Jefferies 2011 Global Healthcare Conference
9. ViroPharma Launches Swell, an Original Documentary Chronicling the Lives of People Living with Hereditary Angioedema
10. ViroPharma Initiates Phase 2 Study of VP 20621 for Prevention of Recurrence of Clostridium difficile Infection (CDI)
11. Halozyme Therapeutics and ViroPharma Announce $83 Million Global Licensing Agreement to Develop Subcutaneous Cinryze® (C1 esterase inhibitor [human])
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... Dec. 6, 2016  BioAtla, LLC, a ... of Conditionally Active Biologic (CAB) antibody therapeutics, ... Group Company, Limited (Sinobioway) selected their first ... specific program candidates and the targeted indications ... and Sinobioway entered into a strategic collaboration ...
(Date:12/6/2016)... , Dec. 6, 2016 In this age ... to be hopeful.  A special kind of sunglasses, from ... anxious life. Photo - http://photos.prnewswire.com/prnh/20161205/445444 ... Robert Buck, the psychotherapist who developed and patented the ... to overcoming anxiety and worry.  "Anxiety doesn,t have ...
(Date:12/5/2016)... Dec. 5, 2016  Zimmer Biomet Holdings, Inc. (NYSE ... pursuant to its previously-announced cash tender offers (the ... table below (collectively, the "Notes"), approximately $2.6 billion in ... and not validly withdrawn on or prior to ... time, today, December 5, 2016 (the "Early Tender ...
Breaking Medicine Technology:
(Date:12/6/2016)... ... December 06, 2016 , ... Specialty ... newly updated International Audit Protocol Consortium (IAPC) EHS audit protocol for Great ... understand the scope of their EHS regulatory obligations and rapidly collect, share, archive, ...
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... ... District , the only authorized OSHA Training Institute Education Center headquartered in Northern ... certificate program focused on providing occupational safety and health training to public sector ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... magazine’s 2017 Training Top 125 for their industry leading training methods that engage ... recognizes USA as among the global elite in employer-sponsored training and development programs. ...
(Date:12/5/2016)... , ... December 05, 2016 , ... "FCPX Overlay Glare ... but natural lighting effect without heavy rendering or complicated compositing," said Christina Austin - ... media to create an organic spectrum of lights that simulates the look of a ...
(Date:12/5/2016)... ... 05, 2016 , ... The Avamere Family of Companies will ... Transitional Care of Puget Sound ; located at 630 S Pearl Street, Tacoma, ... patients recovering from illness or injury with intensive skilled nursing and rehabilitation services. ...
Breaking Medicine News(10 mins):